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ABSTRACT
Vitamin-D insufﬁciency and sarcoidosis are more
common and severe in African Americans (AA) than
Caucasians. In sarcoidosis, substrate-dependent
extrarenal 1,25-dihydroxyvitamin-D (1,25-(OH)2D)
production is thought to contribute to hypercalciuria
and hypercalcemia, and vitamin-D repletion is often
avoided. However, the anti-inﬂammatory properties
of vitamin-D may also be beneﬁcial. We
prospectively examined serum vitamin-D levels,
calcium balance, and the effects of vitamin-D
repletion in 86 AA and Caucasian patients with
biopsy-proven active sarcoidosis from the USA (US)
and Italy (IT) in university-afﬁliated outpatient clinics.
Clinical features, pulmonary function, and
calciotropic hormones were measured. 16 patients
with vitamin-D deﬁciency and normal serum ionized
calcium (Ca2+) were treated with oral ergocalciferol
(50,000 IU/week) for 12 weeks. Baseline mineral
parameters were similar in US (93% AA) and IT
(95% Caucasian) patients irrespective of
glucocorticoid treatment. Pulmonary dysfunction was
less pronounced in IT patients. Nephrolithiasis (in
11% US, 17% IT patients) was associated with
higher urinary calcium excretion. Vitamin-D
deﬁciency was not more prevalent in patients
compared to the respective general populations.
As serum 25-hydroxyvitamin-D (25-OHD) rose
postrepletion, serum 1,25-(OH)2D, γ-globulins, and
the previously elevated angiotensin converting
enzyme (ACE) levels declined. Asymptomatic
reversible increases in Ca2+ or urinary calcium/
creatinine (Ca/Cr) developed in three patients during
repletion. In conclusion, Caucasian and AA patients
show similar calcium and vitamin D proﬁles. The
higher prevalence of hypercalciuria and
nephrolithiasis in sarcoidosis is unrelated to
endogenous vitamin-D levels. Vitamin-D repletion in
sarcoidosis is generally safe, although calcium
balance should be monitored. A hypothesis that
25-OHD repletion suppresses granulomatous
immune activity is provided.
INTRODUCTION
Sarcoidosis is a multisystem disorder of undeter-
mined etiology characterised by widespread
non-caseating granulomatous inﬂammation.1
Patients most commonly present with bilateral
hilar lymphadenopathy, pulmonary inﬁltrates,
and skin and ocular lesions,2 although all
organs may be involved. Activated macrophages
and lymphocytes within the granuloma mediate
extrarenal hydroxylation of 25-hydroxyvitamin
D (25-OHD) to its active metabolite
Signiﬁcance of study
What is already known about this
subject?
▸ Both sarcoidosis and vitamin D deﬁciency
are more common in African Americans
than in Caucasians.
▸ The risk of calcium and vitamin D
disturbance (hypercalcemia, hypercalciuria,
and nephrolithiasis) may also differ
between these two sarcoidosis patient
populations.
▸ Physicians are ambivalent about giving
vitamin D supplementation to patients with
sarcoidosis for fear of mineral side effects.
What are the new ﬁndings?
▸ Sarcoidosis patients from two distinct
ethnic and lifestyle backgrounds are largely
similar in clinical, biochemical and mineral
parameters.
▸ Nephrolithiasis is common in patients with
sarcoidosis and largely driven by
hypercalciuria, but the urinary calcium
excretion rate is not signiﬁcantly associated
with serum vitamin D levels.
▸ The prevalence of vitamin D insufﬁciency is
not higher in patients with sarcoidosis
compared to the general racially matched
population.
▸ Repletion of vitamin D stores in active
sarcoidosis is generally safe and effective.
Repletion is associated with consistent
decreases in serum 1,25-(OH)2D levels and
in the previously elevated serum ACE
levels, suggesting suppression of
granulomatous immune activity.
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1,25-dihydroxyvitamin D (1,25-(OH)2D) independent of
parathyroid hormone (PTH) or calcium regulation3 but
dependent on substrate (25-OHD) concentration.4
Increased 1,25-(OH)2D, in turn, stimulates gastrointestinal
calcium absorption and renal tubular calcium reabsorption,
suppresses PTH production and osteoclast bone resorption,
and promotes osteoblast bone mineralisation, thereby pre-
disposing to the development of hypercalcemia, hypercal-
ciuria and the formation of kidney stones.5–9 Some have
suggested that in sarcoidosis, vitamin D supplementation
may induce hypercalcemia and hypercalciuria at doses nor-
mally insufﬁcient to cause these alterations in healthy sub-
jects. 10–13 On the other hand, vitamin D also possesses
antimicrobial and anti-inﬂammatory properties, and is
known to modulate innate and adaptive immunity and miti-
gate granulomatous inﬂammation.14 15 In this context, low
endogenous vitamin D levels may potentially aggravate
granulomatous inﬂammation in sarcoidosis while repletion
of vitamin D levels may serve a beneﬁcial adaptive role.
The relative importance of these divergent mechanisms
remains to be established.
Both sarcoidosis16 and vitamin D deﬁciency17 18 are
more common and more severe in African Americans (AA)
than in Caucasians. It is plausible that the risk of calcium
and vitamin D disturbance (hypercalcemia, hypercalciuria,
and nephrolithiasis) and the response to vitamin D supple-
mentation may also differ between AA and Caucasian
patients with sarcoidosis. To clarify this issue, we compared
the calcium and vitamin D proﬁles between predominantly
AA sarcoidosis patients in USA (US) and predominantly
Caucasian sarcoidosis patients in Italy (IT), and examined
whether vitamin D repletion raises the risk of hypercalce-
mia and hypercalciuria in these two cohorts.
SUBJECTS AND METHODS
Subjects
A total of 44 patients were recruited from the Sarcoidosis
Clinic at the Parkland Health & Hospital System,
University of Texas Southwestern Medical Center in Dallas,
Texas, USA. A total of 42 patients were recruited from the
outpatient clinics of the Second University of Naples and
the University Federico II of Naples in Naples, and the
University of Padova in Padova, Italy. All patients had
biopsy-proven active granulomatous disease consistent with
the clinical diagnosis of sarcoidosis. Exclusion criteria
included a history of malignancy, creatinine clearance
<70 mL/min, and primary hyperparathyroidism.
Data from a separate multiethnic population-based study
(Dallas Heart Study, DHS19) consisting of 3447 Dallas resi-
dents without sarcoidosis including 1766 AA adults served
as historical control for the assessment of vitamin D status
and comparison with US patients with sarcoidosis. Another
population-based cohort, the Progetto Veneto Anziani
study (Pro.V.A)20 consisting of 1927 Italian Caucasians
without sarcoidosis served as historical control for the
assessment of vitamin D status and comparison with IT
patients with sarcoidosis. The Institutional Review Board
of the University of Texas Southwestern Medical Center
and the Ethics Committee of the University Hospital of the
Second University of Naples approved the protocol.
Written informed consent was obtained from all subjects.
Measurements
Demographic information, as well as clinical and laboratory
proﬁles and treatment regimens, was reviewed. Fasting
venous blood was drawn for serum chemistry, 25-OHD,
1,25-(OH)2D, and PTH, and a 24 h urine sample was col-
lected for the measurement of the total volume, creatinine,
and calcium. None of the patients was taking a pharmaco-
logical repletion dose of vitamin D. A few were taking
over-the-counter vitamin D and or calcium supplements,
which were stopped at least 1 week prior to undergoing
study. Following baseline studies, 16 US patients with
reduced serum 25-OHD (<75 nmol/L) who consented to
undergo repletion therapy were prescribed ergocalciferol
(50,000 IU) orally once a week for 12 weeks. Serum and
24 h urinary calcium levels were measured every 4 weeks.
Adherence was assured by telephone calls, monthly ofﬁce
visits and by pill count at the end of the study.
Analytical procedures
Serum calcium, phosphorus, and creatinine were analyzed
as part of a systematic multichannel analysis (SYNCHRON
CX9 ALX system; Beckman Coulter Fullerton, California,
USA). Serum 1,25-(OH)2D and PTH were measured by
ELISA (IDS Immunodiagnostic Systems, Gaithersburg,
Maryland, USA). Serum 25-OHD was measured by ELISA
(IDS Immunodiagnostic Systems, Gaithersburg, Maryland,
USA) or direct competitive chemiluminescence immuno-
assay (Liaison, DiaSorin, Turin, Italy). γ-Globulins were
quantiﬁed on the basis of serum protein electrophoresis
and immunoﬁxation. Serum angiotensin converting
enzyme (ACE) level was quantiﬁed on the basis of spectro-
photometric quantiﬁcation (absorbance at 340 nm) by the
Mayo Laboratory. Urinary calcium was analyzed by atomic
absorption spectrophotometry.
Statistical analysis
Normal distribution of the variables was established using
histograms and the Wilk-Shapiro normality test. All results
were reported as mean±SD. Two-sample t-tests were used
to evaluate statistical signiﬁcance among groups. The
paired t test was used to compare results before and after
ergocalciferol supplementation. Pearson correlation was
used to analyze the relationship between variables.
Statistical signiﬁcance was set at two-tailed α=0.05.
Signiﬁcance of study
How might these results change the focus of
research or clinical practice?
▸ Physicians can be informed that active sarcoidosis does
not predispose to vitamin D deﬁciency, and race per se
does not inﬂuence the calcium and vitamin D
parameters of these patients.
▸ While repletion of vitamin D stores in active sarcoidosis
is generally safe, calcium balance should be monitored
during repletion.
▸ Repletion of vitamin D stores in active sarcoidosis may
suppress granulomatous immune activity. This novel
observation should be conﬁrmed by further research.
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Microsoft Excel and SAS V.9.4 (SAS Institute, Cary, North
Carolina, USA) were used to perform statistical analysis.
RESULTS
Demographics
Patient characteristics are shown in table 1. Ninety ﬁve per
cent of IT patients were Caucasian while 93% of US
patients were of African descent. Both populations had a
preponderance of middle-aged females. Multisystem organ
involvement was similar in both populations.
Pulmonary functions
Lung involvement, deﬁned by clinical, radiological and/or
PFT abnormalities, was present in all patients. US patients
have lower forced vital capacity (FVC), forced expiratory
volume in 1 s (FEV1), FEV1/FVC ratio, and lung diffusing
capacity for carbon monoxide (DLCO) than IT patients
(table 1).
Clinical, blood, and urinary proﬁles
Twelve of the 86 patients had a documented history of
nephrolithiasis (table 2). Five Italian patients had a history
of nephrolithiasis and two developed nephrolithiasis during
the study period, for a total of seven stone formers. Five
US patients were either diagnosed with nephrolithiasis
during the study period or found to have asymptomatic
stones on abdominal CT. There were no signiﬁcant differ-
ences in age, weight, body mass index (BMI), serum bio-
chemistry, or calciotropic hormones in kidney stone
formers and non-kidney stone formers. Stone formers had
a higher urinary calcium excretion (7.61±3.19 vs 5.04
±3.99 mmol/24 h; p=0.03) and urinary calcium/creatinine
(Ca/Cr) ratio (0.36±0.27 vs 0.59±0.24 mmol/mmol,
p=0.11) than non-stone formers while 24 h urinary
volume was not different (table 2). There was no signiﬁcant
relationship between serum 25-OHD or 1,25-(OH)2D and
24 h urinary calcium excretion (ﬁgure 1) in stone formers
or non-stone formers (p=0.90 and p=0.33, respectively).
Nephrolithiasis
None of the stone forming patients exhibited hypercalce-
mia. IT kidney stone formers had a lower serum phos-
phorus level than those without kidney stone (0.97±0.10 vs
1.23±0.32 mmol/L, p=0.02). Urinary calcium excretion
was higher in IT stone formers versus IT non-stone formers,
although the difference did not reach statistical signiﬁcance,
while urinary calcium excretion was statistically higher in
US stone formers versus non-stone formers (6.24±1.95 vs
3.14±2.15 mmol/24 h, p=0.02) in accordance with the
corresponding fractional excretion of calcium (FE-Ca)
(table 2). Urinary calcium (IT: 7.19±4.34 vs US: 3.59
±2.37 mmol/24 h, p=0.0001) and Ca/Cr ratio (IT: 0.66
±0.31 vs US: 0.33±0.21 mmol/mmol, p=0.02) were con-
siderably higher in IT patients than US patients (table 2).
Serum 1,25-(OH)2D was considerably higher in US patients
than IT patients (IT: 65±29 vs US: 107±44 pmol/L,
p=0.0002), regardless of stone forming conditions,
although 25-OHD levels were not signiﬁcantly different
between IT patients and US patients (IT: 52±27 vs US: 45
±22 nmol/L, p=0.20) (table 2). Other laboratory indices of
sarcoidosis activity did not differ between stone formers
versus non-stone formers within each cohort.
Glucocorticoid therapy
Forty-eight per cent of US patients and 74% of IT patients
were taking prednisone. There were no statistically signiﬁ-
cant differences in baseline parameters between
glucocorticoid-treated and untreated US patients (table 3).
Baseline FEV1 was signiﬁcantly higher in glucocorticoid-
treated patients than untreated IT patients (2.95±0.96 vs
1.96±0.26 L, p=0.0001). Glucocorticoid-treated IT
patients had slightly lower endogenous serum 25-OHD
Table 1 Demographic, pulmonary functions, organ
involvement, and serum 25-OHD levels in US & IT patients,
and control cohorts
Dallas,
USA
Naples/Padova,
Italy p Value
Patients (n) 44 42
Gender (male/female) 5/39 16/26 0.004
Race (Caucasians/AA) 3/41 40/2 <0.0001
Age (years) 49.5±10.2 54.0±13.0 0.07
Height (m) 1.64±0.09 1.62±0.09 0.46
Weight (kg) 83.0±18.6 74.5±12.5 0.02
BMI (kg/m2) 30.9±7.5 28.2±4.4 0.05
Prednisone use (%) 48 74 0.004
Kidney stones (%) 11 17 0.42
Pulmonary functions
FVC (L) 2.46±0.65 3.00±1.00 0.004
FVC (% predicted) 76.8±15.4 94.1±17.2 <0.0001
FEV1 (L) 1.88±0.56 2.72±0.95 <0.0001
FEV1 (% predicted) 71.8±16.7 92.8±19.3 <0.0001
FEV1/FVC ratio 0.76±0.08 0.86±0.18 0.01
FEV1/FVC ratio (% predicted) 0.94±0.10 0.98±0.09 <0.0001
DLCO (mL/mm Hg/min) 14.7±4.2 18.8±7.3 0.01
DLCO (% predicted) 61.4±15.1 76.1±13.8 0.0002
VA (L. BTPS) 3.77±0.91 3.71±2.08 0.91
DLCO/VA 3.90±0.69 3.69±1.98 0.71
Number of active organs involved
1 (Lung only) 14 18 0.29
2 (Lung+1 other) 14 19 0.20
3 (Lung+2 other) 11 4 0.15
4 (Lung+3 other) 3 1 0.33
5 (Lung+4 other) 2 0 0.16
Serum 25-OHD range,
nmol/L
Dallas, US
Patients DHS p Value
<50 (deficiency) 63.60% 80.60% 0.005
50–75 (insufficiency) 22.70% 16.60% 0.28
<75 (deficiency/insufficiency) 86.30% 97.20% <0.0001
>75 (sufficiency) 13.70% 2.80% <0.0001
Serum 25-OHD range,
nmol/L
Naples/Padova, Italy
Patients Pro.V.A p Value
<50 (deficiency) 50.00% 49.70% 0.97
50–75 (insufficiency) 23.80% 22.50% 0.84
<75 (deficiency/insufficiency) 73.80% 72.20% 0.82
>75 (sufficiency) 26.20% 27.80% 0.82
Results are expressed as mean±SD.
25-OHD, 25-hydroxyvitamin-D; AA, African Americans; BMI, body mass index;
BTPS, body temperature and pressure, saturated with water vapor; DLCO,
diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s;
FVC, forced vital capacity; VA, alveolar volume; IT, Italy; US, USA.
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Table 2 Nephrolithiasis profiles in US and IT patients
Dallas, USA
Dallas, US patients Stone No stone p Value Total
Number 5 39 44
Age (years) 42.0±8.9* 50.5±10.1 0.1 49.5±10.2
Height (m) 1.72±0.06 1.63±0.08 0.03 1.64±0.09
Weight (kg) 98.9±30.0 81.0±16.1* 0.26 83.0±18.6
BMI (kg/m2) 34.1±12.6 30.4±6.7 0.55 30.9±7.5
Blood
Creatinine (mmol/L) 115±44 80±27 0.17 88±35
Total calcium (mmol/L) 2.33±0.13 2.38±0.08 0.46 2.35±0.08
Phosphorus (mmol/L) 1.26±0.29 1.1±0.23 0.28 1.1±0.23
Albumin (mmol/L) 5.4±1.0 5.7±0.6 0.48 5.7±0.6
PTH (pmol/L) 3.0±2.1 6.1±3.7 0.03 5.6±3.7
25-OHD (nmol/L) 35±15 47±22 0.43 45±22
1.25-(OH)2D (pmol/L) 120±31* 104±44* 0.43 107±44*
24 h Urine
Volume (L/24 h) 1.96±0.75 1.70±0.77 0.56 1.73±0.76
Calcium (mmol/24 h) 6.24±1.95 3.14±2.15* 0.02 3.59±2.37*
Creatinine (mmol/24 h) 13.30±2.24* 10.84±4.23* 0.08 11.21±4.07*
FE-Ca (%) 2.59±1.37 1.11±0.81* 0.07 1.34±1.03*
Ca/Cr ratio (mmol/mmol) 0.49±0.20 0.31±0.20 0.11 0.33±0.21
Naples/Padova, Italy patients Stone No Stone p Value Total
Number 7 35 42
Age (years) 57.0±5.8* 53.6±14.0 0.37 54.1±13.0
Height (m) 1.64±0.11 1.62±0.08 0.69 1.62±0.09
Weight (kg) 81.3±9.4 73.1±12.7* 0.07 74.5±12.5
BMI (kg/m2) 30.4±4.7 27.7±4.3 0.2 28.2±4.4
Blood
Creatinine (mmol/L) 88±9 80±27 0.74 80±18
Total calcium (mmol/L) 2.50±0.08 2.38±0.10 0.67 2.38±0.10
Phosphorus (mmol/L) 0.97±0.10 1.23±0.32 0.02 1.13±0.29
Albumin (mmol/L) 5.8±1.0 5.4±0.9 0.22 5.4±0.9
PTH (pmol/L) 6.1±4.0 4.6±2.5 0.37 5.0±3.0
25-OHD (nmol/L) 55±20 52±27 0.82 52±27
1.25-(OH)2D (pmol/L) 62±18* 65±31* 0.91 65±29*
24 h urine
Volume (L/24 h) 2.00±0.79 1.77±0.46 0.71 1.79±0.53
Calcium (mmol/24 h) 8.58±3.66 6.89±4.48* 0.31 7.19±4.34*
Creatinine (mmol/24 h) 11.98±4.66* 8.87±2.23* 0.18 10.30±3.76*
FE-Ca (%) 2.30±0.97 2.37±1.53* 0.02 2.33±1.18*
Ca/Cr ratio (mmol/mmol) 0.68±0.25 0.63±0.37 0.83 0.66±0.31
All patients (IT & US) Stone No Stone p Value Total
Number 12 74 86
Age (years) 50.5±10.2 52.0±12.1 0.66 51.8±11.8
Height (m) 1.67±0.10 1.63±0.08 0.16 1.63±0.09
Weight (kg) 88.6±21.3 77.4±15.1 0.11 79.0±16.4
BMI (kg/m2) 32.0±8.6 29.2±5.9 0.3 29.6±6.4
Blood
Creatinine (mmol/L) 95±34 80±25 0.17 82±27
Total calcium (mmol/L) 2.36±0.10 2.37±0.09 0.81 2.37±0.09
Phosphorus (mmol/L) 1.11±0.27 1.12±0.25 0.93 1.11±0.25
Albumin (mmol/L) 5.7±1.0 5.5±0.7 0.68 5.5±0.8
PTH (pmol/L) 4.8±3.6 5.4±3.3 0.6 5.3±3.3
25-OHD (nmol/L) 81±39 85±43 0.84 81±43
1.25-(OH)2D (pmol/L) 94±39 96±44 0.82 96±44
Continued
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than untreated patients (47±20 vs 62±37 nmol/L, respect-
ively) and lower serum 1,25-(OH)2D (57±23 vs 104
±16 pmol/L, respectively), although the differences were
not statistically signiﬁcant. Glucocorticoid-treated IT
patients had signiﬁcantly higher urinary calcium excretion
(8.13±4.29 vs 4.72±3.64 mmol/24 h, p<0.05).
Serum vitamin D levels
As expected, vitamin D deﬁciency (25-OHD <50 nmol/L)
was more prevalent in AA patients than in Caucasian
patients. Insufﬁcient 25-OHD levels (<75 nmol/L) were
observed in 67 of 86 patients (73.8% of IT; 86.3% of US).
A similar percentage (23.8% of IT patients and 22.7% of
US patients) had 25-OHD levels between 50 and 75 nmol/
L, while 50.0% of IT patients and 63.6% of US patients
had 25-OHD levels <50 nmol/L (table 1).
Comparison to ethnic populations
From the DHS database,19 1766 AA subjects without sar-
coidosis served as controls for US patients. The average
serum 25-OHD level in US patients with sarcoidosis was
higher than in DHS AA subjects (45±22 vs 37±17 nmol/L,
p=0.04). The percentage of US patients with deﬁcient
25-OHD levels (<50 nmol/L) was lower than that of DHS
AA subjects (63.6% vs 80.6%, p=0.005), and the percent-
age with optimal (>75 nmol/L) 25-OHD levels was higher
than that of DHS AA subjects (13.7% vs 2.8%,
p<0.0001) (table 1). From the Pro.V.A database,20 1927
Caucasian subjects without sarcoidosis served as controls
for IT patients. Although Pro.V.A subjects were older than
IT patients (73.9±6.7 vs 54.1±13.0 years old, p<0.05),
the distribution among clinically deﬁned 25-OHD ranges
was nearly identical (table 1). Results showed a compar-
able or lower prevalence of reduced endogenous vitamin
D levels compared with that in the corresponding general
populations, that is, the prevalence of vitamin D insufﬁ-
ciency or deﬁciency was not increased among patients
with sarcoidosis.
Effect of vitamin D repletion
Sixteen US patients with reduced baseline 25-OHD levels
(<75 nmol/L) agreed to be treated with ergocalciferol for
12 weeks. Baseline serum calcium, 25-OHD, urinary Ca/Cr
ratio and 1,25-(OH)2D were compared with that obtained
at the end of therapy (ﬁgure 2 and table 4). Following
repletion, the serum 25-OHD level rose in 15 of the 16
patients (average from 42±12 to 82±25 nmol/L,
p<0.0001) while remaining essentially unchanged in 1
patient (table 4). The mean ionized serum calcium level
was unchanged (from 1.33±0.05 to 1.33±0.09 mmol/L,
p=0.67), although 2 patients developed mildly and transi-
ently increased ionized serum calcium postrepletion above
normal range (from 1.38 to 1.50 mmol/L and from 1.30 to
1.48 mmol/L). In one of these 2 patients, postrepletion
serum total calcium (2.40–2.78 mmol/L), urinary calcium
(2.47 to 11.85 mmol/24 h), and urinary Ca/Cr ratio (0.24
to 0.77 mmol/mmol) also mildly exceeded normal limits.
In the other patient with elevated postrepletion serum
Table 2 Continued
All patients (IT & US) Stone No Stone p Value Total
24 h urine
Volume (L/24 h) 1.91±0.74 1.73±0.63 0.46 1.76±0.65
Calcium (mmol/24 h) 7.61±3.19 5.04±3.99 0.03 5.49±3.97
Creatinine (mmol/24 h) 10.44±3.97 12.58±3.65 0.11 10.95±3.96
FE-Ca (%) 2.43±1.11 1.30±1.02 0.01 1.59±1.15
Ca/Cr ratio (mmol/mmol) 0.36±0.27 0.59±0.24 0.02 0.42±0.28
Mean±SD; p value indicates stone versus no stone.
*p<0.05 between corresponding IT & US groups (eg, IT stone former vs US stone former).
1,25-(OH)2D, 1,25-dihydroxyvitamin D; BMI, body mass index; Ca/Cr, calcium to creatine ratio; FE-Ca, fractional excretion of calcium; IT, Italy; OHD, hydroxyvitamin-D;
PTH, parathyroid hormone; US, USA.
Figure 1 Relationship of 24 h urinary calcium excretion to serum 25-OHD (panel a) and 1,25-(OH)2D (panel b) in patients with
sarcoidosis (US and IT combined). There was no signiﬁcant difference between those with or without a history of nephrolithiasis
(p=0.901 and 0.332, respectively). 1,25-(OH)2D, 1,25-dihydroxyvitamin D; 25-OHD, 25-hydroxyvitamin-D; IT, Italy; US, USA.
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ionized Ca2+ level, serum total calcium remained normal
(from 2.38 to 2.55 mmol/L) while 24 h urinary Ca/Cr ratio
was abnormally elevated both pre-repletion and postreple-
tion (from 0.73 to 0.79 mmol/mmol). In a third patient
who showed signiﬁcant postrepletion increases in serum
25-OHD (from 25 to 150 nmol/L), an increase in urinary
calcium (from 2.74 to 6.06 mmol/24 h) and a large
decrease in urinary creatinine (from 8.09 to 2.87 mmol/
24 h) led to a signiﬁcant increase in urinary Ca/Cr ratio
(from 0.34 to 2.11 mmol/mmol) while serum total and
ionized calcium remained within normal ranges (from 2.40
to 2.23 mmol/L and 1.25 to 1.33 mmol/L, respectively).
Thus, in total, 3 patients developed increased blood and/or
urine calcium indices as a result of vitamin D repletion; the
increases were mild, asymptomatic, and reversible.
Unexpectedly, average serum 1,25-(OH)2D levels of 16
US patients declined signiﬁcantly postrepletion from 101
±31 to 52±23 pmol/L (p<0.0001). An absolute decrease
was observed in 14 of the 16 US patients, whereas serum
level did not change in 2 of the 16 patients (ﬁgure 2).
There was no difference in the pre-repletion to postre-
pletion change in serum calcium (p=0.81), 25-OHD
(p=0.68), or 1,25-(OH)2D (p=0.86) levels between
patients who were taking prednisone (n=6) and those not
taking prednisone (n=10).
Serum ACE and γ-globulin levels were also affected fol-
lowing vitamin D repletion. Taking all treated patients
together, the serum ACE level declined slightly but not sig-
niﬁcantly from pre-repletion to postrepletion (1106±687
to 1005±469 nKat/L, p=0.09). However, in the subgroup
of nine US patients with elevated baseline ACE levels,
their ACE levels declined signiﬁcantly from pre-repletion
to postrepletion (1524±553 to 1240±352 nKat/L,
p=0.04). Serum γ-globulins also decreased slightly but
signiﬁcantly from pre-repletion to postrepletion (1.8±0.6
to 1.6±0.6 g/dL, p=0.002) (table 4). Bone-speciﬁc alkaline
phosphatase was not signiﬁcantly affected by repletion
(from 93±44 to 92±39 mg/L, p=0.81).
Pulmonary function changed variably from pre-vitamin D
to post-vitamin D repletion. There were no signiﬁcant
Table 3 Glucocorticoid treatment profiles in US and IT patients
Dallas, USA Naples/Padova, Italy
Prednisone No prednisone p Value Prednisone No prednisone p Value
Number 21 23 31 11
Age (years) 47.3±9.3 51.5±10.9* 0.18 52.0±13.2 60.0±10.5* 0.06
Disease duration (months) 83±72 89±92 0.83 NA NA
Height (m) 1.63±0.10 1.65±0.07 0.65 1.64±0.08 1.60±0.09 0.23
Weight (kg) 79.8±18.6 85.9±18.4* 0.29 75.8±12.55 71.2±12.11* 0.3
BMI (kg/m2) 30.2±8.0 31.5±7.1 0.58 28.4±4.8 27.9±3.6 0.73
Pulmonary function
FVC (L) 2.43±0.71* 2.49±0.60 0.78 3.27±1.07* 2.51±0.48 0.007
FVC (% predicted) 76±17* 77±14* 0.77 93±19* 98±11* 0.36
FEV1 (L) 1.87±0.64* 1.89±0.52 0.89 2.95±0.96* 1.96±0.26 0.0001
FEV1 (% predicted) 71±19* 73±14* 0.78 93±22* 92±10* 0.89
FEV1/FVC 0.76±0.09* 0.76±0.07 0.99 0.88±0.21* 0.78±0.02 0.04
FEV1/FVC (% predicted) 0.93±0.12* 0.94±0.08 0.75 0.99±0.10* 0.94±0.03 0.04
DLCO (mL/mm Hg/min) 13.9±3.4* 15.4±4.8 0.27 19.9±8.2* 15.7±1.9 0.02
DLCO (% predicted) 60±14* 63±16 0.49 77±14* 73±13 0.44
VA (L. BTPS) 3.54±0.69 3.98±1.04 0.14 4.25±1.86 1.91±2.05 0.17
DLCO/VA 3.92±0.70 3.89±0.70 0.89 3.41±1.52 4.61±3.37 0.60
Blood
Creatinine (mmol/L) 80±27 88±27 0.48 80±27 71±9 0.16
Total calcium (mmol/L) 2.35±0.08 2.35±0.10 0.87 2.38±0.10 2.38±0.10 0.98
Phosphorus (mmol/L) 1.03±0.23 1.16±0.23 0.09 1.13±0.32 1.16±0.26 0.88
Albumin (mmol/L) 5.7±0.6 5.7±0.6 0.68 5.4±0.7 5.4±1.3 0.93
PTH (pmol/L) 6.6±3.5 4.6±3.7 0.11 5.0±3.1 5.0±2.6 0.99
25-OHD (nmol/L) 45±20 45±25* 0.91 47±20 62±37* 0.22
1.25-(OH)2D (pmol/L) 104±39* 109±47 0.81 57±23* 104±16 0.09
24 h urine
Volume (L/24 h) 1.62±0.58* 1.86±0.93* 0.39 1.79±0.55* 1.79±0.50* 0.98
Calcium (mmol/24 h) 3.44±1.77* 3.77±2.89 0.68 8.13±4.29* 4.72±3.64 0.03
Creatinine (mmol/24 h) 10.88±4.39 11.52±3.84* 0.66 10.78±4.15 8.72±1.57* 0.23
FE-Ca (%) 1.27±0.69* 1.40±1.30* 0.71 2.53±0.91* 1.82±1.88* 0.59
Ca/Cr ratio (mmol/mmol) 0.34±0.17* 0.33±0.25 0.85 0.70±0.24* 0.51±0.50 0.58
Mean±SD. p Value indicates prednisone versus no prednisone.
*Indicates p<0.05 between corresponding IT & US groups (eg, IT patient with prednisone vs US patient with prednisone). FE-Ca: Fractional excretion of calcium.
1,25-(OH)2D, 1,25-dihydroxyvitamin D; 25-OHD, 25-hydroxyvitamin-D; BMI, body mass index; BTPS, body temperature and pressure, saturated with water vapor;
DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; VA, alveolar volume; IT, Italy; US, USA.
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changes in FVC (2.41±0.72 vs 2.50±0.75 L, p=0.32, %
predicted FVC (76±18 vs 73±16%, p=0.34), FEV1
(1.80±0.62 vs 1.91±0.57 L, p=0.10), or % predicted
FEV1 (70±19 vs 74±17%, p=0.24). There were small
though statistically signiﬁcant increases in pre-repletion
versus postrepletion FEV1/FVC (0.74±0.09 vs 0.77±0.08,
p=0.01) and % predicted FEV1/FVC (93±13 vs 102±11%,
p<0.01). There was a modest and proportional decrease
in prerepletion versus postrepletion DLCO (13.33±3.82
vs 11.86±3.33 mL.(mm Hg.min)−1, p<0.01) and alveolar
volume (VA) (3.40±0.88 vs 3.05±0.86 L, p<0.01) so that
DLCO/VA remained unchanged (3.93±0.56 vs 3.94±0.64,
p=0.89).
DISCUSSION
This prospective study compared calcium and vitamin D
homeostasis in two ethnically and geographically distinct
populations with sarcoidosis. The US patients were mostly
AA (93%) and female (89%), compared to Italian subjects
(95% Caucasians, 62% female). Fewer US patients were on
prednisone treatment than IT patients, and US patients had
worse FVC, FEV1 and DLCO than IT patients. There are
several salient discoveries: First, patients with sarcoidosis
with vastly different ethnic and lifestyle backgrounds
appear to be similar in clinical and biochemical parameters.
Second, nephrolithiasis is common in patients with sarcoid-
osis and is largely driven by hypercalciuria, but the urinary
calcium excretion rate is not signiﬁcantly associated with
serum vitamin D levels. Third, calcium & vitamin D para-
meters do not differ between patients taking glucocorti-
coids versus those not taking glucocorticoids, except that
glucocorticoid-treated IT patients had higher urinary
calcium excretion. Fourth, the prevalence of vitamin D
insufﬁciency is lower in AA patients than in the general AA
population and not different between IT patients with sar-
coidosis and the general IT population. Fifth, there is an
inverse relationship between the changes in 25-OHD levels
and changes in 1,25-(OH)2D following repletion of
vitamin D levels. Sixth, repletion of vitamin D stores in sar-
coidosis is generally safe and effective; mild asymptomatic
reversible hypercalcemia and/or hypercalciuria infrequently
develop during treatment.
Prevalence of nephrolithiasis in sarcoidosis in the litera-
ture ranges between 1.3 and 14% 9 21–25 and hypercal-
ciuria (>5.0 mmol/24 h) has been demonstrated in more
than half of the patients with sarcoidosis on an average
calcium intake of 10.0 mmol/24 h.21 In our study, 7/42
Italian (17%) and 5/44 US (11%) patients had kidney
stones compared to the general Italian and US population
prevalence of 7.5% and 8%, respectively.26 27 Basal levels
of serum 25-OHD did not differ between these two
groups. Urinary calcium excretion was higher in kidney
stone formers than non-kidney stone formers, but did not
bear any signiﬁcant relationship to serum 25-OHD and
1,25-(OH)2D. This vitamin D-independent hypercalciuria
in the sarcoidosis population may reﬂect an impairment in
renal tubular calcium reabsorption,9 and possibly renal
tubular interstitial involvement by sarcoidosis.28–31
In IT patients, lower endogenous 25-OHD and
1,25-(OH)2D levels were observed in glucocorticoid-
treated patients, accompanied by higher urinary calcium
excretion, suggesting possible bone loss. In US patients,
there were no differences in calcium & vitamin D para-
meters between glucocorticoid-treated patients and
non-glucocorticoid-treated patients. However, US patients
had lower FVC, FEV1 and DLCO (% predicted), and
glucocorticoid-treated US patients had lower FVC, FEV1
and DLCO (% predicted) compared to the corresponding
Figure 2 Effects of 12 weeks of ergocalciferol treatment in US patients with sarcoidosis and reduced serum vitamin D levels. (A) Serum
total calcium (p=0.58 pre vs post). (B) 24 h urine Ca/Cr (p=0.18 pre vs post). (C) Serum 25-OHD (p<0.0001 pre vs post). (D) Serum
1,25-(OH)2D (p<0.0001 pre vs post). Individual data points and group mean±SD are shown. (E) Relationship between (post–pre) changes
(Δ) in serum 1,25-(OH)2D and 25-OHD concentrations following ergocalciferol treatment (y=-0.6x—10.1, R
2=0.33, p=0.02). 1,25-(OH)2D,
1,25-dihydroxyvitamin D; 25-OHD, 25-hydroxyvitamin-D; US, USA.
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Table 4 Pre- and post-vitamin D repletion in US patients
Serum 24 h Urine
US Patients
25-OHD
(nmol/l)
1,25-(OH)2D
(pmol/L)
Total Calcium
(mmol/L)
Ionized Ca2+
(mmol/L)
PTH
(pmol/L) ACE (nKat/L)
γ-globulins
(g/dL)
Calcium
(mmol/24 h)
Creatinine
(mmol/24 h)
Ca/Cr
(mmol/mmol) FE-Ca (%)
1 47→85 73→31 2.33→2.38 1.33→1.33 8.1→5.0 101→168 0.6→0.7 2.37→0.70 5.98→2.79 0.40→0.25 1.45→0.80
2 35→72 55→31 2.28→2.23 1.33→1.25 3.4→5.1 2412→1508* 2.2→2.0 6.99→0.62 16.07→4.28 0.44→0.15 1.81→0.61
3 57→90 107→39 2.40→2.35 1.30→1.38 11.2→7.7 0.8→0.7 3.82→2.84 21.70→22.46 0.18→0.13 0.90→0.74
4 55→95 104→65 2.35→2.43 3.1→4.1 1926→1273* 1.7→1.5 4.44→4.77 7.74→10.45 0.57→0.46 2.20→1.72
5 47→107 143→65 2.48→2.58 1.28→1.40 4.1→5.8 1.5→1.4 5.79→8.81 12.35→13.81 0.47→0.64 1.43→1.84
6 55→57 70→75 2.38→2.38 5.4→7.9 1106→905* 1.8→1.4 2.94→3.54 13.42→9.99 0.22→0.36 0.72→1.14
7 37→90 104→44 2.28→2.20 1.28→1.20 6.6→6.3 369→402 0.8→0.8 1.85→2.97 11.74→6.99 0.16→0.43 0.41→1.37
8 32→62 83→36 2.33→2.33 1.30→1.28 12.0→8.3 553→854 1.7→1.2 1.45→3.12 9.42→10.11 0.15→0.31 0.98→1.61
9 52→50 151→122 2.40→2.50 1.33→1.35 4.7→5.4 1374→1072* 2.8→2.7 2.67→1.92 7.64→6.07 0.35→0.32 0.66→0.71
10 42→100 148→49 2.38→2.55 1.38→1.50 2.4→1.3 972→838* 1.8→1.7 9.51→9.03 13.05→11.52 0.73→0.79 2.36→2.26
11 42→95 112→49 2.33→2.33 1.33→1.30 9.1→10.9 1424→1340* 2.0→1.8 0.35→2.89 13.23→17.29 0.03→0.17 0.08→0.49
12 62→70 55→39 2.43→2.40 1.40→1.35 5.3→3.9 1072→1022* 1.6→1.5 1.62→2.00 9.55→7.60 0.17→0.26 0.48→0.85
13 25→150 135→39 2.40→2.23 1.25→1.33 2.3→5.9 754→620 1.9→1.6 2.74→6.06 8.09→2.87 0.34→2.11 0.93→7.39
14 47→60 101→47 2.45→2.30 1.28→1.23 7.4→6.6 1106→1307* 2.4→2.1 1.82→0.90 7.66→7.25 0.24→0.12 0.55→0.34
15 20→62 68→68 2.40→2.78 1.30→1.48 2.9→0.3 2328→1960* 2.4→2.6 2.47→11.85 10.53→15.35 0.24→0.77 1.17→4.58
16 19→57 120→42 2.38→2.33 1.40→1.25 5.3→3.2 720→754 2.0→1.8 3.77→5.36 14.25→16.49 0.26→0.33 0.77→1.09
Mean 42→82 101→52 2.38→2.40 1.33→1.33 5.8→5.5 1106→1005 1.8→1.6 3.41→4.21 11.40→10.33 0.31→0.47 1.06→1.72
SD 12→25 31→23 0.05→0.15 0.05→0.09 3.1→2.6 687→469 0.6→0.6 2.33→3.28 3.98→5.58 0.18→0.49 0.65→1.82
p Value pre vs post 0.0001 <0.0001 0.58 0.67 0.54 0.09 0.002 0.34 0.32 0.18 0.17
Mean±SD, Pre → Post-repletion.
*Indicates patients with elevated baseline angiotensin converting enzyme (ACE). In this subgroup, ACE levels dropped from 1524±553 pre-repletion to 1240±352 nKat/L (p=0.04) postrepletion.
1,25-(OH)2D, 1,25-dihydroxyvitamin D; 25-OHD, 25-hydroxyvitamin-D; Ca/Cr, calcium to creatinine ratio; FE-Ca, fractional excretion of calcium; PTH, parathyroid hormone.
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IT patients, although DLCO per unit alveolar volume
(DLCO/VA) was not different between US and IT patients,
table 1). On the other hand, glucocorticoid-treated US
patients had signiﬁcantly higher 1,25-(OH)2D than
glucocorticoid-treated IT patients (table 3). These observa-
tions suggest that US patients had more severe restriction
of lung volume and greater extrarenal 1,25-(OH)2D con-
version than IT patients. A higher BMI may explain the
lower lung volume in US patients. Lung function para-
meters (as % predicted) were not different between
glucocorticoid-treated and non-glucocorticoid-treated
patients within either the US or IT subgroups (table 3).
As expected, the prevalence of reduced 25-OHD levels
was higher among US AA patients than among IT
Caucasian patients; the difference mirrors that in the
respective general populations (table 1). The prevalence of
vitamin D deﬁciency was lower in US patients with sarcoid-
osis than in the general AA population.
Our prospective data indicate that vitamin D supplemen-
tation for 3 months in vitamin D-deﬁcient patients with
sarcoidosis is effective in repletion of vitamin D stores and
generally safe, although mild elevation of serum and
urinary calcium levels may develop; thus, calcium balance
should be monitored in all patients during vitamin D sup-
plementation. Our results are consistent with the ﬁndings
of a retrospective study of 301 patients with sarcoidosis
that calcium (500 mg daily) and vitamin D (400 IU daily)
supplementation did not raise serum calcium concentra-
tion. 15 In a short-term prospective study of four patients
taking ergocalciferol 10,000 IU daily for 12 days, urinary
calcium rose by 21%, from 3.42 to 4.14 mmol/24 h, 6
which was similar to our observations over 3 months. The
variable and modest postrepletion changes we observed in
lung function measures at rest are inconclusive. Spirometry
indices were unchanged or slightly improved. The reduc-
tions in DLCO and VA with a stable DLCO/VA suggest
reduced inspired lung volume. A larger cohort with longer
treatment duration and measurement of lung volume by
plethysmography will be required to draw deﬁnitive con-
clusions regarding lung function changes.
Vitamin D plays a major role in skeletal health,32 33 as
well as in immune-modulation mediating adaptive immun-
ity34 and suppressing granulomatous inﬂammation. The
serum 25-OHD level is inversely related to sarcoidosis
disease activity.15 An important observation in our study is
that serum 1,25-(OH)2D decreased markedly by ∼50% in
14/16 patients after 3 months of 25-OHD supplementation
(from 101±31 to 52±23 pmol/L, p<0.0001) while
remaining unchanged in 2/16 patients. In contrast, an
earlier study involving four patients treated with vitamin
D2 daily for 12 days reported a mild increase (14%) in
plasma 1,25-(OH)2D from 75 to 86 pmol/L.
6 In our US
patients, baseline serum 1,25-(OH)2D was 65% higher
(table 2) while measures of lung function (FVC, FEV1,
FEV1/FVC and DLCO) were 12–30% lower (table 1) than in
IT patients, consistent with more severe granulomatous
inﬂammation in the predominantly African American
cohort. The marked (average 50%) decrease in serum
1,25-(OH)2D level following 25-OHD supplementation
may be related to the anti-inﬂammatory action of vitamin
D, which has been shown to enhance innate immunity
(eg, promote anti-bactericidal activity) and suppress
adaptive immunity (eg, promote anti-inﬂammation), facili-
tate antigen elimination, and improve the outcome of
granulomatous diseases such as mycobacterial infection
through changes in γ interferon and cathelicidin concentra-
tions.35–37 The high prevalence of vitamin D deﬁciency in
AA38 has been reported to predispose to more aggressive
M. tuberculosis infection,35 and vitamin D supplementation
has shown signiﬁcant beneﬁt in treating tuberculosis in
vitamin D deﬁcient patients.35 38–41 In this context, extrare-
nal production of 1,25-(OH)2D in sarcoidosis, particularly
in patients with vitamin D deﬁciency, may be an adaptive
response by immune-active cells in an attempt to mitigate
antigen-stimulated granulomatous inﬂammation. In our
patients with sarcoidosis, repletion of endogenous vitamin
D stores reduces the need for extrarenal 1,25-(OH)2D pro-
duction, and could explain the fall in serum 1,25-(OH)2D
level. This putative mechanism, while consistent with
current understanding of vitamin D homeostasis, will
require further studies for validation.
The key strengths of this study include a carefully
designed cross-sectional comparison of two ethnically
diverse patients’ cohorts with their respective ethnic
general populations as control and with a subgroup inter-
vention arm (vitamin D supplementation). The key limita-
tions of the study include the small number of patients
given vitamin D supplementation. Also, dietary calcium
intake was not included in our analysis.
In conclusion, our two populations of patients with sar-
coidosis with a diverse genetic background and lifestyle
show similar calcium and vitamin D parameters. Compared
to the ethnically matched healthy controls, patients with
sarcoidosis are not more likely to be vitamin D deﬁcient.
The prevalence of nephrolithiasis is higher in patients with
sarcoidosis than in the general population. The sole identi-
ﬁable risk factor for nephrolithiasis, hypercalciuria, is unre-
lated to the status of vitamin D levels. Repletion of
25-OHD stores in patients with sarcoidosis and vitamin D
insufﬁciency is generally safe, although in a minority of
patients’ serum and/or urinary calcium levels it may
increase above normal; thus, the calcium balance should be
monitored during treatment. In patients with an elevated
basal serum ACE level, repletion of 25-OHD stores is asso-
ciated with a consistent decline in ACE level, suggesting
suppression of granulomatous immune activity. Repletion
of 25-OHD stores is also associated with an unexpected
reduction in serum 1,25-(OH)2D level, suggesting suppres-
sion of autonomous ectopic 1,25-(OH)2D production by
granuloma-associated immune cells. Whether repletion of
25-OHD mitigates the clinical course of granulomatous
inﬂammation remains to be determined.
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